Last €56.30 EUR
Change Today -0.84 / -1.47%
Volume 1.1K
ZEG On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 5:07 AM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (ZEG) Snapshot

Open
€57.20
Previous Close
€57.14
Day High
€57.27
Day Low
€56.23
52 Week High
05/19/14 - €64.20
52 Week Low
10/10/13 - €36.61
Market Cap
71.1B
Average Volume 10 Days
3.4K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/14
P/E TM
--
Dividend
€2.96
Dividend Yield
4.06%
Current Stock Chart for ASTRAZENECA PLC (ZEG)

astrazeneca plc (ZEG) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (ZEG) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (ZEG) Key Developments

AstraZeneca PLC Announces BYDUREON(R) Pen 2 MG

AstraZeneca announced that once-weekly BYDUREON(R) (exenatide extended-release for injectable suspension) Pen 2 mg, a prescription medicine, is now available in pharmacies across the United States. BYDUREON is approved by the U.S. Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. BYDUREON is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise and should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis. BYDUREON is not a substitute for insulin. The concurrent use of BYDUREON with insulin has not been studied and is not recommended. BYDUREON and BYETTA(R) (exenatide) injection contain the same active ingredient and should not be used together. BYDUREON Pen is a pre-filled, single-use pen injector which contains the same formulation and dose as the original BYDUREON single-dose tray. BYDUREON Pen eliminates the need for the patient to transfer the medication between a vial and syringe. The original BYDUREON single-dose tray remains available for current and new patients. BYDUREON is the first once-weekly treatment option for adults with type 2 diabetes, and BYDUREON Pen now offers the same continuous release of exenatide in a pre-filled device. The Prescribing Information for BYDUREON includes a Boxed Warning regarding the risk of thyroid C-cell tumors. It is unknown whether BYDUREON causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. BYDUREON is contraindicated in patients with a personal or family history of MTC, in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or history of a serious hypersensitivity reaction to exenatide or any of the product components. Based on post-marketing data, exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, BYDUREON should be discontinued promptly and not restarted if pancreatitis is confirmed. Other antidiabetic therapies should be considered in patients with a history of pancreatitis. BYDUREON Pen delivers exenatide via microsphere technology in a once-weekly dose requiring no titration. It can be administered at any time of the day, with or without meals. Prior to initiation of BYDUREON Pen, patients should be trained by their healthcare professional.

AstraZeneca and Mitsubishi Tanabe Pharma Corporation Announce Research Collaboration in Diabetic Nephropathy

AstraZeneca and Mitsubishi Tanabe Pharma Corporation, or MTPC, have announced three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development. The collaboration will span from target selection up to the delivery of small molecule candidate drugs. Targets from each company's early research portfolios have been identified as approaches of common interest and additional targets may be included under the collaboration at a later stage, if mutually desired. The research will be performed in parallel at AstraZeneca's Cardiovascular and Metabolic Disease Innovative Medicines Unit (CVMD iMed) in Molndal, Sweden, and at MTPC's facilities in Japan. The parties believe that the collaboration will yield high quality candidate drugs much faster than working alone. There is no financial commitment for the research involved and each party will contribute equal resource at their own cost.

UK High Court Announces Positive Judgment in Teva Pharmaceutical Industries Limited's Patent Case Against AstraZeneca

Teva Pharmaceutical Industries Ltd. announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort(R). The Court agreed with Teva that AstraZeneca's patent covering the SMART indication of Symbicort(R) was obvious, and rejected AstraZeneca's proposed amendments to the patent on the basis that they added matter. The case was brought to facilitate Teva's European launch of its formoterol/budesonide fixed combination product, DuoResp Spiromax(R) which utilizes Teva's innovative Spiromax(R) device technology. This is the latest decision in Teva's favor in respect of AstraZeneca's fixed dose, formoterol/budesonide combination product. The Teva Group has previously successfully revoked patents EP 0,613,371 and also, EP 1,014,993, covering the use of the fixed dose combination in the treatment of asthma and in COPD respectively, and their national equivalents, before the European Patent Office and the Norwegian court.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €56.30 EUR -0.84

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $57.93 USD +0.05
Bayer AG €106.25 EUR -0.31
Celgene Corp $89.46 USD -2.06
GlaxoSmithKline PLC 1,427 GBp -5.50
Novo Nordisk A/S kr273.60 DKK -1.80
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 45.8x
Price/Sales 3.6x
Price/Book 4.2x
Price/Cash Flow 45.9x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.